



1625  
RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE MAR 21 2002

In re application of:  
BENNEKER, et al.

Application No.: 09/855,710

Filed: May 16, 2001

For: 4-Phenylpiperidine Compounds

Atty. Docket: POT-010US3

Examiner: Chang, C.

Group Art Unit: 1625

TECH CENTER 1600/2900  
#4  
MP  
3/23/02

**Supplemental Information Disclosure Statement  
Pursuant To 37 C.F.R. § 1.97(b)**

Assistant Commissioner for Patents  
Washington, D.C. 20231

March 20, 2002

Sir:

Further to the Information disclosure statement filed on February 1, 2002, applicants hereby direct the attention of the Patent and Trademark Office to the document listed on the attached Form PT/SB/08A. Applicants respectfully request that this document be expressly considered during the prosecution of this application, be made of record therein, and appear among the "References Cited" on any patent to issue therefrom. A copy of each listed document is attached.


As the Examiner is aware, the submission of this statement is not to be construed as an admission that any document is prior art to the present invention or that any document is material to patentability as defined in rule 56.

This Information Disclosure Statement is being filed pursuant to 37 C.F.R. § 1.97(b), before the first Office Action on the merits. Therefore, no fee is due.

Please charge any deficiency in fees or credit any overpayment to Deposit Account No.

502109.

Respectfully submitted,

A handwritten signature in dark ink, appearing to read 'Mark R. Buscher', written over a horizontal line.

Mark R. Buscher  
(Reg. No. 35,006)

Synthon Pharmaceuticals, Ltd  
Patent Department  
P.O. Box 161  
Catharpin VA 20143  
703 753 8791